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treatment pathways in a hypothetical NSCLC population in the UK with a baseline 
EGFR mutation prevalence of 16.6%. Model inputs included parameters describing 
mutation testing accuracy, treatment response (EGFR inhibitor, standard chemo 
therapy or best supportive care) and adverse events arising from treatment. Inputs 
were based on published literature and costs in the NHS in England and Wales. The 
model examined cost-effectiveness over the patients’ lifetime. A one-way sensitivity 
analysis was conducted. Results: Using £32,500/QALY as a threshold, the cobas EGFR 
Mutation Test was cost-effective at an incremental cost per QALY gained of £18,394 
for the target population as a result of better test accuracy and lower detection limit 
relative to Sanger sequencing. The cobas EGFR Mutation test was able to correctly 
identify more patients with EGFR mutations (lower rate of false negatives) and more 
appropriately direct patient treatment than Sanger sequencing. ConClusions: The 
cobas EGFR Mutation Test, by correctly identifying more patients for proper treatment, 
can be considered a cost-effective strategy for identification of EGFR mutations in 
locally advanced or metastatic NSCLC patients from a UK payer perspective.
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A CritiCAl APPrAisAl of Cost-EffECtivENEss ANAlysEs of HumAN 
PAPillomAvirus tEstiNg iN CErviCAl sCrEENiNg: mAkiNg APProPriAtE 
ComPArisoNs ANd usEfully iNtErPrEtiNg rEsults
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objeCtives: To critically appraise published cost-effectiveness analyses (CEAs) of 
human papillomavirus (HPV) testing in cervical screening regarding the appropriate-
ness of comparisons between strategies and the usefulness of the interpretation of 
cost-effectiveness estimates. Methods: The PubMed database was searched for rel-
evant CEAs of cervical screening using HPV testing. The identified CEAs were carefully 
appraised for their quality of analyses, reporting and interpretation of results. Specific 
examples of modelling shortcomings were selected as illustrations of what to avoid 
when estimating the cost-effectiveness of HPV-based screening. Results: The review 
identified 29 relevant CEAs. Regarding basic errors, 11 of the 29 calculated the incremen-
tal cost-effectiveness ratios (ICERs) either partly or completely incorrectly. Ten studies 
failed to fully report costs and effects; either simply reporting ICERs or depicting a 
cost-effectiveness plane. Regarding more fundamental errors, 23 failed to include suf-
ficient screening interval comparators against which to meaningfully estimate ICERs; 
effectively leading to average cost-effectiveness ratios being mistakenly identified as 
ICERs, which biases cost-effectiveness ratio estimates downwards. Finally, none of the 
studies gave specific consideration to the magnitude of the change in costs and effects 
of adding HPV testing to a given strategy, either with a simple graphical interpretation 
or with a formal interpretation using the net benefit framework. ConClusions: Model 
specification is typically the most difficult part of a model-based CEA, whereas simulat-
ing relevant strategies is relatively straightforward once the model is built. Similarly, 
once results have been generated, their correct presentation and interpretation is rela-
tively straightforward. However, this analysis shows that these relatively easy aspects 
of CEA are being performed poorly in the HPV screening literature. Consequently, a few 
simple improvements to basic aspects of CEAs of HPV-based screening could greatly 
enhance the usefulness of such analyses to decision makers.
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objeCtives: ALK-targeted therapy with crizotinib offers significant improvement 
in clinical outcomes for the treatment of EML4–ALK fusion positive NSCLC. We 
estimated the cost-effectiveness of EML4-ALK testing in combination with first-
line crizotinib for ALK positive NSCLC in Ontario. Methods: A cost-effective-
ness analysis was conducted, using a Markov model from the Canadian public 
health (Ontario) perspective and a lifetime horizon in Stage IV NSCLC patients 
with non-squamous histology. Transition probabilities and mortality rates were 
calculated from the Ontario Cancer Registry and Cancer Care Ontario New Drug 
Funding Program (CCO NDFP). Costs were obtained from the Ontario Case Costing 
Initiative, CCO NDFP, University Health Network and the literature. Population-based 
ALK testing included initial IHC testing followed by FISH confirmation for posi-
tive cases. Results: The strategy of genomic testing linked to targeted crizotinib 
treatment gained 0.11 QALYs compared to no testing or crizotinib treatment in the 
advanced non-squamous NSCLC population. The incremental cost was CAD $4,179 
per patient compared to the previous standard of care without ALK testing; the 
incremental cost-effectiveness ratio for the base case was $392,538 per QALY. The 
incremental cost and ICER for crizotinib therapy in known ALK positive advanced 
NSCLC patients was $96,554 and $254,617/QALY. The cost of testing was less rel-
evant to the ICER at a biomarker frequency of 7% and higher. The major drivers 
of cost-effectiveness are drug cost and low biomarker frequency in the popula-
tion. ConClusions: EML4–ALK genomic testing in combination with crizotinib 
treatment for all Stage IV non-squamous NSCLC patients is not cost-effective in the 
setting of high drug costs and a low biomarker frequency in the general population. 
Modifying these key drivers will be important in improving the cost-effectiveness 
and accessibility to novel therapies with major clinical benefit in advanced NSCLC.
PCN106
ovErviEw oN Cost-EffECtivENEss rEsults of dECisioN-ANAlytiC 
studiEs for tHE trEAtmENt of multiPlE myElomA
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to induction cost and percentage transplants. At a willingness-to-pay threshold 
of 35,000€ per QALY gained, VTD has a 57.1% probability to be cost-effective in 
this setting. ConClusions: VTD induction is a cost-effective strategy for ndMM 
patients eligible for ASCT in Germany compared to TD.
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A Cost-EffECtivENEss ANAlysis of CisPlAtiN Plus PEmEtrExEd doublEt 
iNduCtioN trEAtmENt followEd by PEmEtrExEd mAiNtENANCE 
ComPArEd witH bEvACizumAb Plus CisPlAtiN Plus gEmCitAbiNE triPlEt 
iNduCtioN trEAtmENt followEd by bEvACizumAb mAiNtENANCE for 
NoN-squAmous NsClC iN swEdEN
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objeCtives: This analysis compares the cost effectiveness (CE) of an induction 
and maintenance sequence of a cisplatin plus pemetrexed (cis+pem) doublet fol-
lowed by pemetrexed, with that of a bevacizumab (7.5mg or 15mg) plus cispl-
atin plus gemcitabine (bev+cis+gem) triplet followed by bevacizumab (7.5mg or 
15mg) for the treatment of non-squamous non-small cell lung cancer (NSCLC) 
in Sweden. Methods: As no head-to-head trial data are available comparing 
these relevant regimens in the first-line induction and maintenance treatment 
settings, decision modelling and evidence synthesis were used to estimate 
CE. A series of network meta-analyses were performed to obtain hazard ratios 
for overall survival (OS) and progression-free survival (PFS) for each induction 
and maintenance comparator, and odds ratios for response for induction com-
parators. Bevacizumab doses were pooled in the meta-analyses. The CE model 
was structured using an area-under-the-curve approach. Costs and benefits 
were discounted at 3% per annum, consistent with Swedish practice. Results: 
Cis+pem induction followed by pemetrexed maintenance was associated with 
a higher median PFS, OS, total life-years gained and quality-adjusted life-
years (QALYs) than the bevacizumab triplets. Total costs were 416,478Kr for the 
bev(7.5mg)+cis+gem induction triplet plus bevacizumab 7.5mg maintenance 
sequence, 478,862Kr for the cis+pem doublet followed by pemetrexed maintenance 
sequence, and 541,677Kr for the bev(15mg)+cis+gem induction triplet followed 
by bevacizumab 15mg maintenance sequence. Total QALYs were 0.73 and 0.97 
for the bevacizumab triplets and pemetrexed induction and maintenance 
sequence. The incremental cost-effectiveness ratio (ICER) of cis+pem followed by 
pemetrexed compared with bev(7.5mg)+cis+gem followed by bevacizumab 7.5mg 
was 260,831Kr (30,477Euro). The higher bevacizumab dose of 15mg was dominated 
by the cis+pem followed by pemetrexed sequence. The results of the probabilis-
tic analysis support these results. ConClusions: The results of the CE analysis 
suggest that cis+pem doublet induction followed by pemetrexed maintenance is 
a cost-effective treatment sequence compared with the bevacizumab options for 
NSCLC in Sweden.
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A Cost-EffECtivENEss ANAlysis of AxitiNib ANd sorAfENib for 2Nd 
liNE trEAtmENt of AdvANCEd rENAl CEll CArCiNomA AftEr fAilurE of 
CytokiNEs iN tHE uNitEd stAtEs
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objeCtives: To assess the cost-effectiveness of axitinib compared to sorafenib from 
the perspective of a US third-party payer for second-line treatment of patients with 
advanced RCC who failed cytokines. Methods: Phase III AXIS trial reported that 
axitinib increased median progression free survival (PFS) compared to sorafenib 
(12.0 vs. 6.6 months, p< 0.0001), while overall survival (OS) showed no difference 
(29.4 vs. 27.8 months, p= 0.144) in patients failing treatment with cytokines. A cohort 
partition model was constructed to estimate direct medical costs and health out-
comes, discounted at 3.0% per annum. Patients were apportioned into 3 health 
states (progression-free, progressed and dead) based on OS and PFS Kaplan-Meier 
curves from the AXIS trial. Active treatment was applied until progression, fol-
lowed by best supportive care (BSC) thereafter. The wholesale acquisition costs and 
adverse event (AE) costs were obtained from published sources. AE rates and utility 
values were informed by the AXIS trial. US administrative claims data (MarketScan®) 
was analyzed to estimate routine care costs. Probabilistic sensitivity analysis (PSA) 
was conducted. Results: The total per-patient lifetime costs were estimated to be 
$242,750 for axitinib and $168,880 for sorafenib and 84% of the cost difference was 
due to the higher total medication cost of axitinib. The quality-adjusted life-years 
(QALY) gained on axitinib vs. sorafenib was 1.3 vs. 1.2 and the incremental cost-
effectiveness ratio (ICER) was $683,209/QALY. 100% of the PSA iterations showed 
that axitinib was more expensive than sorafenib and the QALY difference between 
axitinib and sorafenib was no greater than 0.7. ConClusions: For post-cytokine 
subgroup, axitinib resulted in an ICER > $650,000/QALY versus sorafenib due to 
high drug costs and lack of OS benefit, indicating that axitinib may not present 
good value for money as 2nd line treatment of advanced RCC when compared to 
sorafenib in the US.
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Cost-EffECtivENEss of CobAs® Egfr mutAtioN tEst vErsus sANgEr 
sEquENCiNg iN tHE trEAtmENt of loCAlly AdvANCEd or mEtAstAtiC 
NsClC: A PAyEr PErsPECtivE iN tHE uNitEd kiNgdom
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objeCtives: We explored the cost-effectiveness of using the CE-IVD marked cobas® 
EGFR Mutation Test versus Sanger sequencing for identifying EGFR mutations in locally 
advanced or metastatic NSCLC patients from a UK payer perspective. Methods: A 
decision-tree model was developed to compare testing methodologies and resulting 
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Physician Fee Schedule and represented in 2013 US dollars. Average wholesale prices 
for a 30-day supply of AA and ENZA were $7,674 and $8,940, respectively. One-way 
sensitivity analyses were performed against all probability, utility, and cost values 
incorporated into this cost-effectiveness model. Results: In this analysis, AA pro-
vides substantial saving with $13,322 per patient versus ENZA. The main drivers 
of the model are drug costs, health utility values, and efficacy (OS and rPFS). The 
robustness of the results was supported by sensitivity analyses. ConClusions: 
Given similar OS benefits, AA is cost saving compared with ENZA for the treatment 
of patients with mCPRC post-docetaxel based on US data.
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ComPArAtivE study of tHE Cost-EffECtivENEss of trAstuzumAb iN tHE 
trEAtmENt of brEAst CANCEr iN diffErENt CouNtriEs
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objeCtives: Pharmacoeconomic evaluations are more critical in developing 
countries in which economic effects of new and expensive therapies have sig-
nificant impact on patients, insurance companies and the health systems. Since 
cost-effectiveness studies are too costly and time consuming, in these countries 
new medications are often being used in daily practice before being well docu-
mented as cost-effective interventions. This would force health organizations 
to perform comparative studies as alternatives to cost-effectiveness analysis. 
Trastuzumab, an anti-cancer monoclonal antibody which was approved by FDA 
in 1998, is an expensive medicine introduced to the Iranian pharmaceutical market 
since 2003, with an annual usage cost of 308,352,730,640 Rials ($ US 25,000,000) in 
2010. Methods: A systematic review on electronic medical databases including 
the Cochrane, CRD, EMBASE, HEED, MEDLINE, and PubMed, covering the years 2000 
to 2009, was performed using relevant key words to extract publications investi-
gating cost-effectiveness and efficacy of trastuzumab in breast cancer treatment. 
The Incremental Cost-Effectiveness Ratios (ICERs) were compared with a criterion 
introduced by WHO. Results: The reported ICERs were between $90,118/QALY 
to $217,264/QALY and $13,361/QALY to $65,250/QALY in metastatic and adjuvant 
breast cancer therapy, respectively. The metastatic ICERs were 8 to 20 folds of the 
GDP per Capita in Iran whereas the adjuvant phase ICERs were 1.2 to 6 folds of it. 
Sensitivity analysis showed the results are more sensitive to discount rate, drug 
regimen cost, duration of survival benefits, as well as the risk of relapse and metas-
tasis. ConClusions: Trastuzumab therapy in metastatic breast cancer cannot be 
cost effective in Iran, however as adjuvant therapy it is still a challenging issue. 
Unlimited access to this medicine would not be rational and recommendations 
with an approach to optimize its usage, e.g. administration in younger patients 
with poor prognosis and higher risk of relapse or using clean rooms to reduce drug 
wasting, are strongly advised.
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tHE Cost-EffECtivENEss of bENdAmustiNE-rituximAb vErsus 
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objeCtives: To determine the cost-effectiveness of bendamustine-rituximab 
(Ben-R) versus fludarabine-rituximab (Fdb-R) in patients with iNHL who have pro-
gressed following treatment with rituximab or a rituximab-containing regimen in 
Mexico. Methods: An economic model was constructed from the Mexican public 
payer perspective, with a 35-year (lifetime) horizon and a discount rate of 5%. The 
model included three health states, progression-free (PF), progressive disease (PD), 
and death, which were associated with utility weights of 0.81, 0.62 and 0, respec-
tively. Clinical inputs (response rates, Kaplan-Meier curves, hazard ratios (HRs) and 
adverse event rates) were from the Stil NHL 2-2003 study. Resource use data were 
from interviews with Mexican hematologists treating iNHL patients. Unit costs were 
obtained from Mexican Social Security Institute (IMSS) and were expressed as 2013 
Mexican Pesos. Univariate and probabilistic sensitivity analyses were conducted to 
determine the key drivers of cost-effectiveness, and uncertainty around the results, 
respectively. Results: Total cost of Ben-R was $1,726,828 and total cost of Fdb-R 
was $1,640,024. Ben-R patients accrued more LYs (5.82 vs. 4.73), QALYs (4.22 vs. 3.29), 
and PF LYs (3.37 vs. 1.96) compared to Fdb-R patients. The ICERs were $79,890 (cost 
per LY), $92,788 (cost per QALY) and $61,486 (cost per PF LY). Univariate sensitivity 
analysis revealed that the ICER per LY was most sensitive to the PF survival (PFS) and 
overall survival (OS) HRs for Ben-R vs Fdb-R and the use of bone marrow transplants 
in the PD state. Probabilistic sensitivity analysis with 1,000 iterations estimated that 
Ben-R will be cost effective over 90% of the time at a willingness-to-pay threshold 
of $125,085. ConClusions: At a willingness-to-pay of $125,085 (GDP per capita of 
Mexico) Ben-R is cost effective versus Fdb-R.
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objeCtives: In Romania the estimated incidence of metastatic renal cancer 
(mRCC) is about 1500 cases; less than 400 patients receive full reimbursement for 
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objeCtives: To provide an overview on published decision-analytic models 
evaluating treatment strategies for multiple myeloma (MM) focusing on the cost-
effectiveness results. Methods: A systematic literature search was performed in 
the electronic databases Pubmed, NHS EED and the Tufts CEA Registry to identify 
studies evaluating MM treatment strategies using mathematical decision-analytic 
models. To meet the inclusion criteria, models were required to compare different 
treatment strategies, to be published as full text articles in English, and com-
prise relevant clinical health outcomes over a defined time horizon and popula-
tion. We used evidence tables to summarize methodological characteristics and 
economic results. For comparability, all economic results were transferred into 
2012 US Dollar. We used Purchasing Power Parity to convert the currency into US 
Dollar of the same year. For converting US Dollar from step one into US Dollars 
2012, we used Consumer Price Index rates for the relevant year. Results: We 
found eleven decision-analytic modeling studies. Economic evaluations were 
included in all studies. Eight studies reported cost-utility results. The modeling 
approaches applied included a decision tree model, Markov cohort model, discrete 
event simulations, partitioned survival analyses and area under the curve models. 
Time horizons ranged from seven years to lifetime. Half of the models chose the 
perspective of the health care system, while other perspectives were societal, 
third party payer and government payer. Among others, two studies reported cost-
effectiveness of autologous transplantation vs. standard-dose melphalan with an 
ICER of $31,263 /life-year gained (LYG) and $36,778/LYG. One study reported that 
bortezomib vs. lenalidomide plus dexamethasone is cost saving, while another 
comparable study reported an ICUR for lenalidomide plus dexamethasone vs. 
bortezomib of $22,301/QALY. ConClusions: We identified several well-designed 
cost-effectiveness/cost-utility models using a broad variety of different modeling 
approaches. Results of most of the studies were not comparable due to different 
treatment strategies, target population and settings.
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ECoNomiC EvidENCE of surgiCAl ProCEdurEs iN CANCEr: A systEmAtiC 
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objeCtives: To examine the empirical and methodological cost-effectiveness evi-
dence of surgical interventions for breast, colorectal, and prostate cancer. Methods: 
Systematic searches of seven databases including MEDLINE, EMBASE, CDSR,HTA, 
DARE, EconLit and NHSEED, research registers, the National Institute of Health and 
Care Excellence (NICE) website and conference proceedings was conducted in April 
2012. Studies were included if they evaluated the cost-effectiveness of a surgical 
procedure in either breast, colorectal or prostate cancer and reported cost per quality 
adjusted life-year or cost per life-year results. The quality of the studies included was 
assessed in terms of meeting essential, preferred, and UK specific requirements for 
economic evaluations. Results: The 17 (breast= 3,colorectal= 7,prostate= 7) studies 
which satisfied the inclusion criteria covered a broad range of settings with 9 set in 
European and 8 in non-European locations. Just a third (11/17) was published within 
the last 10 years. In terms of the essential quality criteria; the populations, inter-
ventions and comparators were generally well defined. However, very few studies 
were informed by the results of literature reviews or synthesised clinical evidence. 
Although the interventions had potential differential effects on recurrence and mor-
tality rates, some studies used relatively short time horizons. Although univariate 
sensitivity analyses were reported in all studies, less than a third characterised all 
uncertainty with a probabilistic sensitivity analysis. While a third of studies incorpo-
rated patients’ health-related quality of life data, only 4 of the 17 studies used social 
tariff values. ConClusions: There is very little recent robust evidence describing 
the cost-effectiveness of surgical interventions in these indications. Many of the 
more recent publications did not satisfy the essential methods requirements, such 
as using synthesising clinical evidence informed by a systematic literature review. 
Given the ratio of potential benefit and harm associated with surgery in cancer, there 
is an urgent need to conduct additional robust economic evaluations in this area.
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objeCtives: With approvals of abiraterone acetate (AA) and enzalutamide (ENZA) 
in the past 2 years, the treatment landscape has shifted dramatically for metastatic 
castration-resistant prostate cancer (mCRPC) patients who failed docetaxel-based 
chemotherapy. There is increasing interest in the relative cost-effectiveness of these 
therapies. The objective of this study was to assess the cost-effectiveness of AA 
versus ENZA among individuals with mCRPC post chemotherapy from a payer per-
spective. Methods: A survival-based Markov cohort model consisting of 3 health 
states, progression-free, progressed, and dead, was developed to project over 10 
year period. Progression between states was determined by overall survival (OS) 
and radiographic progression free survival (rPFS). An indirect treatment comparison 
was conducted to determine the relative efficacy of AA and ENZA (data reported 
separately). Utilities were mapped from FACT-P to EQ-5D based on a review of the 
literature. Drug acquisition costs in the US were used since ENZA was approved only 
in the US at the time of analysis. Costs of scheduled and unscheduled follow-up 
visits were obtained from the Centers for Medicare Services Drug Payment Table and 
